Goldman Sachs initiated coverage of Jazz Pharmaceuticals with a Buy rating and $169 price target. Jazz has a diversified global portfolio of commercial assets across two verticals of neuroscience and oncology, with the company on track to achieve its “Vision 2025” goal of $5B revenue, the analyst tells investors in a research note. The firm says that while the investor debate has been on the outlook for the company’s sleep business, it is optimistic on Jazz’s emerging pipeline to support its longer-term growth profile. It sees the stock as attractive at current levels.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JAZZ:
- Jazz presents OS, longer follow-up data from HERIZON-BTC-01 trial
- Catherine Sohn to Retire from Jazz Pharmaceuticals Board
- Jazz Pharmaceuticals: FDA accepts, grants Priority Review of BLA for zanidatamab
- Jazz announces strategic collaboration with Life Science Cares
- Jazz Pharmaceuticals price target lowered to $200 from $230 at Barclays
Questions or Comments about the article? Write to editor@tipranks.com